Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Intravitreal triamcinolone has been effective for central macular thickness reduction and
concomitant visual acuity improvement in patients with diabetic macular edema (DME). VEGF is
a very effective inducer of permeability, being 50.000 times more potent than histamine, and
may exert its effect on retinal vascular permeability by altering tight-junctions proteins,
such as occluding and VE-cadherin. Based on these principles, there is a rationale for
anti-VEGF agents treatment of increased retinal capillary permeability conditions, such as
diabetic macular edema. Therefore, the purpose of this study is to evaluate the effects of
intravitreal bevacizumab and intravitreal triamcinolone associated to laser photocoagulation
for diabetic macular edema.
Phase:
Phase 3
Details
Lead Sponsor:
University of Sao Paulo
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo